SG11202003407VA - PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF - Google Patents
PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOFInfo
- Publication number
- SG11202003407VA SG11202003407VA SG11202003407VA SG11202003407VA SG11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA
- Authority
- SG
- Singapore
- Prior art keywords
- tbk
- pyrimidine
- inhibitor compounds
- ikke
- ikke inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573251P | 2017-10-17 | 2017-10-17 | |
| PCT/US2018/056190 WO2019079373A1 (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003407VA true SG11202003407VA (en) | 2020-05-28 |
Family
ID=64110185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003407VA SG11202003407VA (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230019491A1 (en) |
| EP (1) | EP3697772A1 (en) |
| JP (1) | JP7266592B2 (en) |
| KR (1) | KR20200072519A (en) |
| CN (1) | CN111247135A (en) |
| AU (1) | AU2018352699A1 (en) |
| BR (1) | BR112020007466A2 (en) |
| CA (1) | CA3078579A1 (en) |
| IL (1) | IL273891A (en) |
| MX (1) | MX2020003507A (en) |
| RU (1) | RU2020115596A (en) |
| SG (1) | SG11202003407VA (en) |
| TW (1) | TWI802604B (en) |
| WO (1) | WO2019079373A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI802605B (en) * | 2017-10-17 | 2023-05-21 | 德商默克專利有限公司 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF |
| CN112552280A (en) * | 2019-09-25 | 2021-03-26 | 常州强力先端电子材料有限公司 | High-acid-yield sulfimide photo-acid generator |
| EP4054583A4 (en) * | 2019-11-07 | 2023-10-25 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| CN117447407B (en) * | 2023-12-19 | 2024-06-11 | 潍坊医学院 | Preparation method of JAK2 inhibitor Pacritinib and intermediate thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2911139A1 (en) * | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | New 2,4-diaminopyrimidine derivatives useful for treating inflammatory diseases, diabetes or cancer |
| PT2200436E (en) * | 2007-09-04 | 2015-04-29 | Scripps Research Inst | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| MX2012004313A (en) * | 2009-10-12 | 2012-07-20 | Myrexis Inc | Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon. |
| GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| CN103732067A (en) * | 2011-04-12 | 2014-04-16 | 美国阿尔茨海默病研究所公司 | Compounds,compositions and therapeutic uses thereof |
| DE102011112978A1 (en) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | benzonitrile derivatives |
| MX2017015357A (en) * | 2015-06-29 | 2018-03-16 | Merck Patent Gmbh | Tbk/ikke inhibitor compounds and uses thereof. |
-
2018
- 2018-10-17 JP JP2020521968A patent/JP7266592B2/en active Active
- 2018-10-17 AU AU2018352699A patent/AU2018352699A1/en not_active Abandoned
- 2018-10-17 EP EP18797386.2A patent/EP3697772A1/en not_active Withdrawn
- 2018-10-17 CN CN201880067979.0A patent/CN111247135A/en active Pending
- 2018-10-17 BR BR112020007466-7A patent/BR112020007466A2/en unknown
- 2018-10-17 RU RU2020115596A patent/RU2020115596A/en unknown
- 2018-10-17 US US16/756,769 patent/US20230019491A1/en not_active Abandoned
- 2018-10-17 CA CA3078579A patent/CA3078579A1/en active Pending
- 2018-10-17 SG SG11202003407VA patent/SG11202003407VA/en unknown
- 2018-10-17 KR KR1020207014078A patent/KR20200072519A/en not_active Application Discontinuation
- 2018-10-17 MX MX2020003507A patent/MX2020003507A/en unknown
- 2018-10-17 WO PCT/US2018/056190 patent/WO2019079373A1/en unknown
- 2018-10-17 TW TW107136567A patent/TWI802604B/en active
-
2020
- 2020-04-07 IL IL273891A patent/IL273891A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020115596A (en) | 2021-11-18 |
| TW201922735A (en) | 2019-06-16 |
| KR20200072519A (en) | 2020-06-22 |
| RU2020115596A3 (en) | 2021-11-18 |
| WO2019079373A1 (en) | 2019-04-25 |
| MX2020003507A (en) | 2020-07-22 |
| TWI802604B (en) | 2023-05-21 |
| US20230019491A1 (en) | 2023-01-19 |
| EP3697772A1 (en) | 2020-08-26 |
| CN111247135A (en) | 2020-06-05 |
| JP2020537671A (en) | 2020-12-24 |
| BR112020007466A2 (en) | 2020-09-24 |
| CA3078579A1 (en) | 2019-04-25 |
| AU2018352699A1 (en) | 2020-05-28 |
| IL273891A (en) | 2020-05-31 |
| JP7266592B2 (en) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201707641B (en) | Tbk/ikke inhibitor compounds and uses thereof | |
| IL273236A (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| IL270330B (en) | Beta-lactamase inhibitors and uses thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| HK1251547A1 (en) | Pyrimidine or pyridopyridone compound and application thereof | |
| EP3572400C0 (en) | Ezh2 inhibitor and use thereof | |
| PT3543240T (en) | Urat1 inhibitor and use thereof | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| SG11202003407VA (en) | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| PL3621694T3 (en) | Lrrc33 inhibitors and use thereof | |
| GB201714745D0 (en) | New compounds and uses | |
| SG11202004877UA (en) | Sulfonamide compounds and use thereof | |
| IL262400A (en) | Erbb inhibitors and uses thereof | |
| ZA201901773B (en) | Pde4 inhibitor | |
| GB201714740D0 (en) | New compounds and uses | |
| GB201714734D0 (en) | New compounds and uses | |
| IL263949A (en) | Complement inhibitors and uses thereof | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, compositions comprising same and uses thereof | |
| GB201714736D0 (en) | New compounds and uses | |
| GB201712110D0 (en) | New compounds and uses | |
| HK1255029A1 (en) | Gelatinase inhibitors and use thereof | |
| ZA202002825B (en) | Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof | |
| IL265617B (en) | 1-phenylpropanone compounds and use thereof | |
| EP3442533A4 (en) | Tg2 inhibitor compounds and uses thereof | |
| GB201719327D0 (en) | New compounds and uses |